Abstract
We conducted this study to evaluate the efficacy and safety of adjuvant chemotherapy using taxane plus carboplatin (CBDCA) for high-risk stage IB-IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Thirty-seven patients were eligible. Pelvic lymph node involvement and/or parametrial invasion were defined as high-risk factors. The patients were treated with 6 cycles of paclitaxel (PTX, 175 mg/m(2)) or docetaxel (DTX, 60 mg/m(2)) followed by CBDCA (area under the curve, 6) every 3 weeks. The primary end point was 2-year progression-free survival (PFS) rate, and the secondary end point was the assessment of adverse events. Twenty-two patients received PTX/CBDCA (TC) chemotherapy, and the remaining 15 patients underwent DTX/CBDCA (DC) chemotherapy. The 2-year PFS rate was 62.1% (95% confidence interval, 44.6%-75.5%). Patients receiving DC chemotherapy showed a better 2-year PFS rate compared to those with TC chemotherapy, but the difference was not statistically significant (80.0% vs 50.0%, P = 0.1400). The most common grade 3/4 adverse events were hematologic toxicities, which were generally well tolerable. Nonhematologic toxicity was generally mild. Taxane and CBDCA combination chemotherapy,...Continue Reading
References
Oct 1, 1995·Gynecologic Oncology·P J EifelT L Smith
Aug 23, 1997·Lancet·F LandoniC Mangioni
May 18, 1999·Gynecologic Oncology·M LahousenR Winter
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W A PetersD S Alberts
Oct 4, 2000·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·T IrieN Terakawa
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P CurtinR D Alvarez
Jul 21, 2004·Gynecologic Oncology·Annie YessaianBradley J Monk
Jul 30, 2005·Gynecologic Oncology·E KastritisM A Dimopoulos
Nov 23, 2005·Gynecologic Oncology·Muneaki ShimadaNaoki Terakawa
Jan 24, 2006·International Journal of Radiation Oncology, Biology, Physics·Marvin RotmanRichard J Zaino
Jun 17, 2006·Gynecologic Oncology·Nobuhiro TakeshimaKatsuhiko Hasumi
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 22, 2008·The Journal of Obstetrics and Gynaecology Research·Masayoshi HosakaNoriaki Sakuragi
Jul 21, 2009·Gynecologic Oncology·Wei-Chung HsuShu-Ching Chan
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkDavid Cella
May 7, 2010·Japanese Journal of Clinical Oncology·Yuzuru NiibeKazushige Hayakawa
Nov 9, 2011·Journal of Surgical Oncology·Masayoshi HosakaNoriaki Sakuragi
Jan 24, 2012·Gynecologic Oncology·Vijaya GalicJason D Wright
Feb 2, 2012·Gynecologic Oncology·Kanyarat KatanyooSumonmal Manusirivithaya
Jun 26, 2012·Gynecologic Oncology·Seiji MabuchiTadashi Kimura
Mar 22, 2014·Molecular and Clinical Oncology·Muneaki ShimadaJunzo Kigawa
Aug 1, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Mikio MikamiUNKNOWN Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group
Aug 26, 2014·Gynecologic Oncology·Peter G RoseGillian M Thomas
Mar 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ryo KitagawaHiroyuki Yoshikawa
Mar 25, 2015·International Journal of Clinical Oncology·Yasuhiko EbinaHiroyuki Yoshikawa
Citations
Mar 18, 2017·Current Oncology Reports·Masayuki FutagamiToru Sugiyama
Dec 24, 2019·Japanese Journal of Clinical Oncology·Muneaki ShimadaNobuo Yaegashi
Jul 7, 2017·Medical Oncology·Maki TaniokaJunzo Kigawa
Apr 8, 2021·International Journal of Clinical Oncology·Muneaki ShimadaJunzo Kigawa